NTT-CORPORATION
22.7.2022 08:09:09 CEST | Business Wire | Press release
NTT Corporation (“NTT”) screened the “International Conference for Visualizing our Future brought about by Technological Innovation feat. IOWN” at the Short Shorts Film Festival & Asia 2022 (SSFF & Asia 2022), one of the largest international short film festivals in Asia recognized by the U.S. Academy Awards. The conference featured a discussion between NTT, experts of various fields, and international directors who have won the Grand Prix at SSFF & Asia about a vision of the future influenced by technological innovation like IOWN1 .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005622/en/
After filmmakers from around the world watched the screening, NTT issued a call for short films featuring the theme of our ideal lives created alongside scientific and technological innovation. From the entries, we will create one short film that best captures the theme.
You can watch the conference on the official SSFF & Asia 2022 website .
NTT is working toward the realization of a smart society founded on IOWN, which is the next-generation communication platform. In November 2021, we founded the Natural Society Lab to communicate how the technology incorporating IOWN will benefit society and enrich people's lives. We also create short films to convey to the masses our vision of a world where innovation in science and technology flourish alongside ideal human life.
Experts and filmmakers that took part in the conference included the Yubari International Fantastic Film Festival Executive Producer and Shinichiro Kumagaya, a professor from the Research Center for Advanced Science and Technology at the University of Tokyo. The conference included discussions on the following four topics:
Part 1: What is "Natural Society Lab"?
Part 2: Natural Society Lab & Daily Life - in the Context of Film & Science
Part 3: Creators' Take on Visualizing Thought
Part 4: Expressing the World Realized by IOWN
Conference Speakers:
Akiko Kudo
NTT Senior Vice President
Head of Public Relations
and Deputy Head of Business strategy*
*2022.June
Junji Watanabe
NTT Communication Science Laboratories
Senior Distinguished Research Scientist
Shinichiro Kumagaya
Pediatrician and
Associate Professor at the Research Center
for Advanced Science and Technology
Shuichi Fukatsu
Executive Producer
for Yubari International Fantastic Film Festival
Kristof Deak
Filmmaker
Genevieve Clay-Smith
Filmmaker
The short films selected and produced through the competition will be released next year.
1
IOWN (Innovative Optical and Wireless Network)
A future communication platform utilizing cutting-edge optical-related technology and information processing technology to realize a smart world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005622/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
